AU2005216095B2 - Salivary mRNA profiling, biomarkers, and related methods and kits of parts - Google Patents

Salivary mRNA profiling, biomarkers, and related methods and kits of parts Download PDF

Info

Publication number
AU2005216095B2
AU2005216095B2 AU2005216095A AU2005216095A AU2005216095B2 AU 2005216095 B2 AU2005216095 B2 AU 2005216095B2 AU 2005216095 A AU2005216095 A AU 2005216095A AU 2005216095 A AU2005216095 A AU 2005216095A AU 2005216095 B2 AU2005216095 B2 AU 2005216095B2
Authority
AU
Australia
Prior art keywords
saliva
cell
mrna
bodily fluid
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005216095A
Other languages
English (en)
Other versions
AU2005216095A1 (en
Inventor
Yang Li
Maie A. R. St. John
David T. W. Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2005216095A1 publication Critical patent/AU2005216095A1/en
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA reassignment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Alteration of Name(s) of Applicant(s) under S113 Assignors: THE REGENTS OF THE UNIVERSITY OF C ALIFORNIA
Application granted granted Critical
Publication of AU2005216095B2 publication Critical patent/AU2005216095B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AU2005216095A 2004-02-20 2005-02-17 Salivary mRNA profiling, biomarkers, and related methods and kits of parts Ceased AU2005216095B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54650704P 2004-02-20 2004-02-20
US60/546,507 2004-02-20
US54652104P 2004-02-21 2004-02-21
US60/546,521 2004-02-21
PCT/US2005/005263 WO2005081867A2 (en) 2004-02-20 2005-02-17 Salivary mrna profiling, biomarkers, and related methods and kits of parts

Publications (2)

Publication Number Publication Date
AU2005216095A1 AU2005216095A1 (en) 2005-09-09
AU2005216095B2 true AU2005216095B2 (en) 2009-09-17

Family

ID=34915575

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005216095A Ceased AU2005216095B2 (en) 2004-02-20 2005-02-17 Salivary mRNA profiling, biomarkers, and related methods and kits of parts

Country Status (10)

Country Link
US (3) US10072297B2 (https=)
EP (1) EP1730304B1 (https=)
JP (2) JP4880484B2 (https=)
KR (2) KR20070004725A (https=)
CN (1) CN1977051B (https=)
AU (1) AU2005216095B2 (https=)
CA (1) CA2558666C (https=)
IL (1) IL177579A (https=)
NO (1) NO340089B1 (https=)
WO (1) WO2005081867A2 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4880484B2 (ja) * 2004-02-20 2012-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 唾液ｍＲＮＡプロファイリング、バイオマーカーならびに関連した方法およびキット
US7727715B2 (en) 2004-03-30 2010-06-01 Vector Tobacco, Inc. Global gene expression analysis of human bronchial epithelial cells exposed to cigarette smoke, smoke condensates, or components thereof
KR20070065869A (ko) * 2004-07-21 2007-06-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 타액 트랜스크립톰 진단법
WO2008001357A2 (en) * 2006-06-26 2008-01-03 Technion Research & Development Foundation Ltd. Methods and kits for diagnosing cancer
EP2083087B1 (en) * 2006-10-12 2013-05-15 Niigata University Method for determining tongue cancer
JP2008295327A (ja) * 2007-05-30 2008-12-11 Fujifilm Corp 口腔扁平上皮癌の検出方法、及び抑制方法
WO2008157501A1 (en) * 2007-06-15 2008-12-24 The Regents Of The University Of California Salivary exon core transcriptome
WO2009012340A2 (en) 2007-07-16 2009-01-22 California Institute Of Technology Microfluidic devices, methods and systems for detecting target molecules
US8476008B2 (en) * 2008-07-23 2013-07-02 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
US20110143962A1 (en) 2008-08-04 2011-06-16 Institut Clinident Method of evaluating oral cancer risk in human
US20130143747A1 (en) * 2011-12-05 2013-06-06 Myriad Genetics, Incorporated Methods of detecting cancer
US9075060B2 (en) 2009-06-16 2015-07-07 Technion Research & Development Foundation Limited Methods for diagnosing oral or oral-pharyngeal cancer
WO2010151789A1 (en) * 2009-06-25 2010-12-29 The Regents Of The University Of California Salivary transcriptomic and microbial biomarkers for pancreatic cancer
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
EP2475989A4 (en) 2009-09-09 2013-02-27 Gen Hospital Corp USE OF MICROVESICLES IN THE ANALYSIS OF KRAS MUTATIONS
JP2011072229A (ja) * 2009-09-29 2011-04-14 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた下咽頭がんの診断・治療選択
US8309299B2 (en) * 2010-05-19 2012-11-13 Hoffmann-La Roche Inc. Combination therapy and method for assessing resistance to treatment
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
JP6219721B2 (ja) 2010-11-10 2017-10-25 エキソソーム ダイアグノスティックス インコーポレイテッド 核酸含有粒子の単離および該粒子からの核酸の抽出のための方法
CN103827303B (zh) * 2011-09-26 2021-10-22 普瑞阿那利提克斯有限公司 细胞外核酸的稳定化和分离
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
JP6329072B2 (ja) 2011-09-26 2018-05-23 キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞外核酸の安定化および単離
CN108267581A (zh) 2012-08-24 2018-07-10 耶鲁大学 用于高通量多重检测的系统、装置和方法
CN104755628B (zh) 2012-09-25 2019-03-01 凯杰有限公司 生物样品的稳定化
US20140188442A1 (en) * 2012-12-27 2014-07-03 Pearson Education, Inc. System and Method for Selecting Predictors for a Student Risk Model
US11525155B2 (en) 2013-03-18 2022-12-13 Qiagen Gmbh Stabilisation of biological samples
JP6407248B2 (ja) 2013-03-18 2018-10-17 キアゲン ゲーエムベーハー 細胞外核酸の安定化および単離
WO2014182598A1 (en) * 2013-05-06 2014-11-13 Physicians Choice Laboratory Services, Llc Diagnostic assay combining cellular and cell free nucleic acid
EP3578984A3 (en) * 2013-10-28 2020-03-04 Salivatech Co., Ltd. Salivary biomarkers for oral cancer
US20210005324A1 (en) * 2018-08-08 2021-01-07 Hc1.Com Inc. Methods and systems for a health monitoring command center and workforce advisor
US12027243B2 (en) 2017-02-17 2024-07-02 Hc1 Insights, Inc. System and method for determining healthcare relationships
GB201417281D0 (en) * 2014-09-30 2014-11-12 Ge Healthcare Uk Ltd Methods and devices relating to the detection of oral cancer biomarkers
CN112782140A (zh) 2014-12-03 2021-05-11 伊索普莱西斯公司 细胞分泌特征的分析和筛选
EP3256849A4 (en) * 2015-02-09 2018-12-05 Abogen, Inc. Devices, solutions and methods for sample collection related applications, analysis and diagnosis
US11353448B2 (en) 2015-02-13 2022-06-07 California Institute Of Technology Methods and compositions for quantifying metabolites and proteins from single cells
KR20170120124A (ko) 2015-02-24 2017-10-30 루프레히트-칼스-유니페어지테트 하이델베르크 암 검출을 위한 바이오마커 패널
CA2989199A1 (en) 2015-07-01 2017-01-05 Duke University Methods to diagnose and treat acute respiratory infections
CN106446599A (zh) * 2015-08-11 2017-02-22 中国科学院青岛生物能源与过程研究所 一种筛选婴幼儿龋病的口腔致病性生物标记物的方法
EP3377645B1 (en) 2015-11-20 2023-10-04 Qiagen GmbH Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
GB201602210D0 (en) 2016-02-08 2016-03-23 Ucl Business Plc Detection of cancer
EP3510398B1 (en) 2016-09-12 2026-02-25 Isoplexis Corporation System and methods for multiplexed analysis of cellular and other immunotherapeutics
EP4036578A1 (en) 2016-11-11 2022-08-03 Isoplexis Corporation Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells
CN110226084A (zh) 2016-11-22 2019-09-10 伊索普莱克西斯公司 用于细胞捕获的系统、装置和方法，以及其制造方法
US20200157637A1 (en) * 2017-05-26 2020-05-21 Board Of Regents, The University Of Texas System Targeting of anaplastic lymphoma kinase in squamous cell carcinoma
CN111226118A (zh) * 2017-10-27 2020-06-02 加利福尼亚大学董事会 用于牙龈炎的唾液细胞外rna生物标记物
US20210018507A1 (en) * 2018-03-04 2021-01-21 Mazumdar Shaw Medical Foundation Sall.ivary protein biomarkers for the diagnosis and prognosis of head and neck cancers, and precancers
WO2020128546A1 (en) * 2018-12-20 2020-06-25 Kromat Műszerforgalmazó Kft. A simple, non-invasive method for diagnosing oral cancer
EP3671213A1 (en) * 2018-12-20 2020-06-24 Kromat Muszerforgalmazó Kft. In vitro method for the diagnosis of malignant conditions
JP2020195314A (ja) * 2019-05-31 2020-12-10 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
JP7373843B2 (ja) * 2019-12-19 2023-11-06 国立大学法人東海国立大学機構 感染の原因生物を予測するための予測装置、予測プログラム及び予測方法
CN113985033B (zh) * 2021-10-19 2025-02-14 中山大学附属第八医院（深圳福田） 一种用于诊断骨质疏松症发生肌少症的生物标记物及检测试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511805B1 (en) * 1996-03-15 2003-01-28 The Penn State Research Foundation Methods for detecting papillomavirus DNA in blood plasma and serum
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
US6617112B2 (en) * 2000-10-11 2003-09-09 Monsanto Technology Llc Methods for gene array analysis of nuclear runoff transcripts

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US20020102553A1 (en) * 1997-10-24 2002-08-01 University Of Rochester Molecular markers for the diagnosis of alzheimer's disease
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
DE60239470D1 (de) 2001-07-25 2011-04-28 Oncomedx Inc Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
JP4880484B2 (ja) * 2004-02-20 2012-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 唾液ｍＲＮＡプロファイリング、バイオマーカーならびに関連した方法およびキット

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511805B1 (en) * 1996-03-15 2003-01-28 The Penn State Research Foundation Methods for detecting papillomavirus DNA in blood plasma and serum
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
US6617112B2 (en) * 2000-10-11 2003-09-09 Monsanto Technology Llc Methods for gene array analysis of nuclear runoff transcripts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN Z ET AL. "Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer ". Clinical Cancer Research, 1999, vol. 5, pages 1369-1379 *
HUANG Y-T ET AL. "Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ cells". Cancer Research, 1999, vol. 59, pages 1599-1605 *

Also Published As

Publication number Publication date
US10072297B2 (en) 2018-09-11
HK1095163A1 (en) 2007-04-27
AU2005216095A1 (en) 2005-09-09
WO2005081867A2 (en) 2005-09-09
KR20070004725A (ko) 2007-01-09
CN1977051A (zh) 2007-06-06
IL177579A (en) 2012-03-29
JP2011229532A (ja) 2011-11-17
US20080280772A1 (en) 2008-11-13
IL177579A0 (en) 2006-12-10
NO20064226L (no) 2006-11-16
CA2558666C (en) 2015-11-24
US20190040471A1 (en) 2019-02-07
JP4880484B2 (ja) 2012-02-22
US9983210B2 (en) 2018-05-29
CA2558666A1 (en) 2005-09-09
EP1730304A2 (en) 2006-12-13
WO2005081867A3 (en) 2006-07-06
JP5367760B2 (ja) 2013-12-11
NO340089B1 (no) 2017-03-06
JP2007522819A (ja) 2007-08-16
CN1977051B (zh) 2013-07-17
EP1730304B1 (en) 2013-01-02
EP1730304A4 (en) 2007-10-24
US20140249236A1 (en) 2014-09-04
KR20130018438A (ko) 2013-02-22

Similar Documents

Publication Publication Date Title
AU2005216095B2 (en) Salivary mRNA profiling, biomarkers, and related methods and kits of parts
Li et al. Salivary transcriptome diagnostics for oral cancer detection
EP4428157A2 (en) Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
CN113557310A (zh) 用于乳腺癌预后的转录组谱分析
JP5745500B2 (ja) 肝臓癌予後マーカー
Grade et al. Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/β-catenin signaling pathway in human rectal carcinomas
AU2005274974B2 (en) Salivary transcriptome diagnostics
WO2020231997A1 (en) Non-cording rna for treatment of bladder cancer
Shi et al. Field-effect-informed urine liquid biopsy for bladder cancer
US20240319192A1 (en) Use of immune content scores diagnostically to predict responsiveness of prostate cancer patients to immunotherapy
HK1095163B (en) Methods for salivary mrna profiling
EP1954830B1 (en) Methods and kits for breast cancer prognosis
KR20220112450A (ko) 담즙 및 ddPCR 분석을 이용한 담도암 진단용 조성물 및 이의 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired